SANOFI Innovation Awards Program
Internal deadline: September 15, 2018
Johns Hopkins University School of Medicine and sixteen other major peer institutions (Brigham and Womens Hospital, Columbia University, Massachusetts General Hospital, Boston Childrens Hospital, University of Pennsylvania, Weill Cornell Medical Center, Stanford University, UCLA, UCSF, New York University, Northeastern University, Childrens Hospital of Philadelphia, Dana Farber Cancer Center, Sinai Health (Toronto), Sunnybrook Health (Toronto) and University Health Network (Toronto)) have entered into an agreement with SANOFI for their fourth Innovations Awards Program. If proposed projects are selected they will receive a one-year award for $125,000 including indirect costs, which may be renewable for an additional year and/or successful Innovation Awards projects may receive additional ongoing sponsored awards beyond the Innovation Program. The Innovation Awards Agreement includes pre-negotiated terms of the Innovation Awards and additional follow-on Sponsored Awards with publication rights for the investigators and an IP option for SANOFI.
To be eligible for consideration, projects will go through a two stage review; 1) first submit to Karen Falter (email@example.com) a brief non-confidential pre-proposal by September 15, 2018, and 2) SANOFI will select from the pre-proposals those projects that will be asked to prepare a more detailed confidential proposal by October 15th, under guidelines issued at that time. The requested detailed proposals will be due on November 5th and will be reviewed by a Joint Scientific Committee that includes a scientist from each of the participating institutions as well as from SANOFI. Selected awards are expected to be announced early December.
Please submit innovative translational research ideas that align with SANOFI's stated areas of interest in the RFP document. Unfunded previous internal and external proposals and new proposal ideas can be used. Funding Awards are only available for research conducted by researchers at this institution that does not involve a third-party collaborator. A third party-collaborator is considered (i) any researcher employed by an institution or entity that is not an institution/entity participating in the iAwards program, (ii) a funding source involving any organization or entity other than a state or federal government agency, or (iii) a third party for which the confidential information, materials, or methods or models described in the proposal involve third-party rights that may restrict the Parties intellectual property rights as set forth in the Funding Award Agreement template.
If you have any questions, please contact Karen Falter (firstname.lastname@example.org).
Application deadline: August 16, 2018
The NIH Director's Early Independence Award supports exceptional investigators who wish to pursue independent research essentially directly after completion of their terminal doctoral/research degree or end of post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. Applications are welcome from individuals of diverse backgrounds and perspectives and in any topic of relevance to the broad mission of NIH. The NIH Director's Early Independence Award is part of the High-Risk, High-Reward Research program funded through the NIH Common Fund. All Common Fund initiatives invite investigators to develop bold, innovative, and often risky approaches to address major problems that are especially daunting or to seize new opportunities that offer the potential for rapid progress. Johns Hopkins may nominate up to 2 investigators for this $1,250,000 (direct costs only) award.
Eligibility & Requirements:
Internal Nomination Process:
For more information visit https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-18-010.html. Questions? Comments? Email the Research Development Team at email@example.com.
No application deadline
The Michael J. Fox Foundation is sponsoring a $2 million prize to the first team to develop a viable selective alpha-synuclein PET tracer and agree to make that tracer available broadly.
The ability to image alpha-synuclein deposition
in the brain would be a game-changing achievement for the Parkinson's
disease (PD) field. The accumulation of aggregated alpha-synuclein is
a pathological hallmark of PD and a priority target for drug development
given its hypothesized contribution to neurodegeneration. In vivo imaging
of alpha-synuclein pathology could be useful as a biomarker of the presence
of disease and disease progression and as a pharmacodynamic tool for
drug development. With this prize, the Foundation seeks to attract research
teams and accelerate momentum to speed the development of such a tracer.
Contestants: Anyone is eligible for
the prize who agrees to all contest rules. Contestants may be MJFF funded
or not and can be from either academia or industry.
Criteria for winning: The winning contestant
must demonstrate that the radiotracer binds with relatively high selectivity
to alpha-synuclein according to pre-specified criteria and must demonstrate
proof-of-concept in human subjects, including people with Parkinson's
disease and/or another synucleinopathy. See below for more details on
Timeline: There is no deadline
for submissions. The $2 million award will be issued to the first
contestant who submits compelling evidence of a viable selective tracer
and agrees to its widespread use. If no award is given by mid-2018,
The Michael J. Fox Foundation will evaluate the state of the field and
utility of such a prize.